Transactions & Cas
Schellenberg Wittmer successfully represented Actavis in patent litigation against Eli Lilly
09.03.2017
Actavis, an affiliate of Teva Pharmaceutical Industries, one of the leading pharmaceutical companies worldwide, was successfully represented in a patent litigation by Schellenberg Wittmer’s IP Team (lead counsel Andrea Mondini) against Eli Lilly.
After having dismissed Eli Lilly's request for preliminary injunctions, the Swiss Federal Patent Court granted Actavis a declaratory judgment on the merits that Actavis' pemetrexed diacid product does not infringe Eli Lilly's patent EP 1 313 508 B1 claiming pemetrexed disodium for cancer treatment. This patent is heavily litigated in several countries, including Germany and the United Kingdom.
Partager
Plus d'informations
bundespatentgericht.chContact
Schellenberg Wittmer a conseillé le financement de l'acquisition de Neschen Coating par ATP
08.10.2024
Schellenberg Wittmer a conseillé ams-OSRAM sur la vente de ses actifs "Passive Optical Components"
07.10.2024
Schellenberg Wittmer conseille Meeberg Leasing Switzerland AG dans le cadre d'une opération de financement sécurisée de EUR 63 millions
26.09.2024